IL-6-induced pathophysiology during pre-eclampsia: Potential therapeutic role for magnesium sulfate?

International Journal of Interferon, Cytokine and Mediator Research

Volumn 3, Issue 1, 2011, Pages 59-64

  la Marca, Babbette ^a   Brewer, Justin ^a   Wallace, Kedra ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Hypertension; Inflammation; Interleukin 6; Pregnancy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CD4 ANTIGEN; CYTOKINE; INTERLEUKIN 6; MAGNESIUM SULFATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR FUNCTION; CD4+ T LYMPHOCYTE; CYTOKINE RELEASE; DOPPLER FLOWMETRY; HUMAN; ISCHEMIA; MATERNAL HYPERTENSION; MOLECULAR PATHOLOGY; NEUROPROTECTION; NONHUMAN; PLACENTA ISCHEMIA; PREECLAMPSIA; REVIEW; SEIZURE; TH17 CELL; VASCULAR RESISTANCE;

EID: 80051742165     PISSN: None     EISSN: 1179139X     Source Type: Journal    
DOI: 10.2147/ijicmr.s16320     Document Type: Review

References (51)

1. Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension. 2003;41:437-445.
2. Thadhani RI, Johnson RJ, Karumanchi SA. Hypertension during pregnancy: a disorder begging for pathophysiological support. Hypertension. 2005;46:1250-1251.
3. Roberts JM, Gammill H. Insulin resistance in pre-eclampsia. Hypertension. 2006;47:341-342.
4. Roberts JM, Gammill HS. Pre-eclampsia: recent insights. Hypertension. 2005;46:1243-1249.
5. Germain AM, Romanik MC, Guerra I, et al. Endothelial dysfunction: a link among pre-eclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension. 2007;49:90-95.
6. Blaauw J, Graaff R, van Pampus MG, et al. Changes in endothelial function precede the clinical disease in women in whom pre-eclampsia develops in response: endothelial function and pre-eclampsia. Hypertension. 2006;47:e14-e15.
7. Khan F, Belch JJF, Macleod M, Mires G. Changes in endothelial function precede the clinical disease in women in whom pre-eclampsia develops. Hypertension. 2005;46:1123-1128.
8. Myers J, Mires G, Macleod M, Baker P. In pre-eclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension. 2005;45:258-263.
9. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with pre-eclampsia. JAMA. 2001;285:1607-1612.
10. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during pre-eclampsia: linking placental ischemia with endothelial dysfunction. Hypertension. 2001;38(3 Pt 2):718-722.
11. Granger JP, Alexander BT, Bennett WA, Khalil RA. Pathophysiology of pregnancy-induced hypertension. Microcirculation. 2002;9:147-160.
12. Roberts JM, Von Versen-Hoeynck F. Maternal fetal/placental interactions and abnormal pregnancy outcomes. Hypertension. 2007;49:15-16.
13. Sabour S, Franx A, Rutten A, et al. High blood pressure in pregnancy and coronary calcification. Hypertension. 2007;49:813-817.
14. Mello G, Parretti E, Marozio L, et al. Thrombophilia is significantly associated with severe pre-eclampsia: results of a large-scale, casecontrolled study. Hypertension. 2005;46:1270-1274.
15. Irgens HU, Reisater L, Irgens LM, Lie RT, Roberts JM. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study Pre-eclampsia and cardiovascular disease later in life: who is at risk? BMJ. 2001;323:1213-1217.
16. Poston L. Endothelial dysfunction in pre-eclampsia. Pharmacol Rep. 2006;58 Suppl:69-74.
17. McMaster MT, Ahou Y, Fisher SJ. Abnormal placentation and the syndrome of pre-eclampsia. Semin Nephrol. 2004;24(6):540-547.
18. Sharma A, Satyam A, Sharma JB. Leptin, IL-10, and inflammatory markers (TNF-alpha, IL-6 and IL-8) in preeclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol. 2007;58(1):21-30.
19. Girardi G, Yarilin D, Thurman JM, et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. JEM. 2006;203:2164-2175.
20. Souza AS, Amorim MM, Coutinho IC, Lima MM, Noronha NC, Figueria JN. Effect of the loading dose of MgSO4 on the parameters of Doppler flow velocity in the uterine, umbilical and middle cerebral arteries in severe pre-eclampsia. Hypertens Pregnancy. 2010;29:123-134.
21. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of pre-eclampsia. Am J Reprod Immunol. 1997;37:240-249.
22. Wang Y, Walsh SW. TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas. J Reprod Immunol. 1996;32:157-169.
23. Freeman DJ, McManus F, Brown EA, et al. Short-and long-term changes in plasma inflammatory markers associated with pre-eclampsia. Hypertension. 2004;44:708-714.
24. Armanini D, Calo LA. Aldosterone, inflammation, and pre-eclampsia. Hypertension. 2005;45:e10.
25. LaMarca BB, Bennett WA, Alexander BT, Cockrell K, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. Hypertension. 2005;46:1022-1025.
26. LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension. 2005;46:82-86.
27. Lucovnik M, Kornhauser-Cerar L, Premru-Srsen T, Gmeiner-Stopar T, Derganc M. Neutrophil defensins but not IL-6 in vaginal fluid after preterm premature rupture of membranes predict fetal/neomatal inflammation and infant neurological impairment. Acta Obstet Gynecol Scand. May 12, 2011. [Epub ahead of print].
28. Duncombe G, Veldhuizen RA, Gratton RJ, Han VK, Richardson BS. IL-6 and TNF alpha across the umbilical circulation in term pregnancies: relationship with labor events. Early Hum Dev. 2010;86:113-117.
29. Leik C, Walsh SW. Neutrophils infiltrate resistance-sized vessels of subcutaneous fat in women with pre-eclampsia. Hypertension. 2004;44:72-77.
30. Gadonski G, LaMarca BB, Sullivan E, Bennett W, Chandler D, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension. 2006;48:711-716.
31. Abbus A. Cellular and Molecular Immunology. 5th ed. Philadelphia, PA: Elsevier; 2005.
32. Wulff H, Pennington M. Targeting effector memory T-cells with Kv1.3 blockers. Curr Opin Drug Discov Devel. 2007;10:438-445.
33. Rutella S. Granulocyte colony-stimulating factor for the induction of T-cell tolerance. Transplantation. 2007;84(1 Suppl):S26-S30.
34. Santner-Nanan B, Peek MJ, Khanam R, et al. Systemic increase in the ratio between Foxp3 and IL-17-producing CD4aaT Cells in healthy pregnancy but not in pre-eclampsia. J Immunol. 2009;183:7023-7030.
35. LaMarca B. Progress toward identifying potential markers for pre-eclampsia: role of agonistic autoantibodies to the angiotensin II type I receptor. Hypertension. 2010;55:236-237.
36. LaMarca B. The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during pre-eclampsia. Minervia Ginecologica. 2010;62:105-120.
37. Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology (Oxford). 2005;44 Suppl 2:ii3-ii7.
38. Heo YJ, Joo YB, Oh HJ, et al. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4(r) T cell population of rheumatoid arthritis patients. Immunol Lett. 2010;127:150-156.
39. Hasegawa M, Fujimoto M, Takehara K, Sato S. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci. 2005;39:1-7.
40. Granger JP, LaMarca BBD, Cockrell K, et al. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol Med. 2006;122:383-392.
41. LaMarca BB, Speed J, Fournier L, Babcock SA, Berry H, Cockrell K, Granger JP. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of TNF alpha blockade. Hypertension. 2008;52:1-5.
42. LaMarca BB, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP. Elevated agonistic autoantibodies to the angiotensin type 1 (AT1-AA) receptor in response to placental ischemia and TNF alpha in pregnant rats. Hypertension. 2008;52:7-11.
43. Speed J, Fournier L, Cockrell K, Dechend R, Granger J, LaMarca B. IL-6 induced hypertension in pregnant rats is associated with production agonistic autoantibodies to the angiotensin II type I receptor. Presented at Experimental Biology; 2009 Apr 5; New Orleans, LA.
44. Duley L, Farrell B, Spark P, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulfate? The Magpie Trial: a randomized placebo-controlled trial. Lancet. 2002;359:1877-1890.
45. Duley L, Henderson-Smart D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev. 2003;4:CD000128.
46. Duley L, Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev. 2010;12:CD000127.
47. Duley L, Henderson-Smart D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;11:CD000025.
48. Euser AG, Cipolla MJ. Magnesium sulfate for the treatment of eclampsia, a brief review. Stroke. 2009;40:1169-1175.
49. Holcberg G, Amash A, Sapir O, et al. Different effects of magnesium sulfate and angiotensin II on the capacity of the fetal and maternal compartments of normal human placenta to secrete TNF-alpha and IL-6. J Reprod Immunol. 2006;69:115-125.
50. Amash A, Holcberg G, Sheiner E, Huleihel M. Magnesium sulfate normalizes placental interleukin-6 secretion in pre-eclampsia. J Interferon Cytokine Res. 2010;30:683-690.
51. Tam Tam HB, Dowling O, Xue X, Lewis D, Rochelson B, Metz CN. Magnesium sulfate ameliorates maternal and fetal inflammation in a rat model of maternal infection. April 2011. Am J Obstet Gynecol. 2011;204:364. e1-e8.